Peptide Comparison
SLU-PP-332vsPancragen
A groundbreaking exercise mimetic compound that tricks your body into thinking it's training for a marathon—boosting metabolism, burning fat, and building endurance without you ever having to hit the gym.
Tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that binds ACCT sequences in pancreatic gene promoters with 3-fold greater affinity than related peptides, stimulates beta-cell differentiation through Pdx1/Pax6/NGN3 transcription factor activation, and corrects impaired glucose tolerance in primates more physiologically than glimepiride
At a Glance
Quick
comparison
Dose Range
SLU-PP-332
250–1500 mcg
Pancragen
50–500 mcg
Frequency
SLU-PP-332
Once daily
Pancragen
Multiple times daily
Administration
SLU-PP-332
Oral
Pancragen
Intramuscular injection
Cycle Length
SLU-PP-332
8-12 weeks
Pancragen
8-12 weeks
Onset Speed
SLU-PP-332
Moderate (1-2 weeks)
Pancragen
Gradual (3-4 weeks)
Evidence Level
SLU-PP-332
Strong preclinical (extensive animal studies)
Pancragen
Limited human trials
Efficacy
Benefit
ratings
Metabolic Enhancement
Exercise Mimetic
Fat Loss Support
Blood Sugar Balance
Pancreas Protection
Metabolic Aging Support
Technical Data
Compound
specifications
SLU-PP-332
Molecular Formula
C18H14N2O2
Molecular Weight
290.3 g/mol
Half-Life
Estimated 4-8 hours
Bioavailability
Moderate (oral); High (injection)
CAS Number
863971-53-5
Pancragen
Molecular Formula
C26H36N6O9
Molecular Weight
576.6 g/mol
Half-Life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic modifications to pancreatic gene expression (primate studies showed partial effects 3 weeks post-treatment); metabolized to constituent amino acids
Bioavailability
Demonstrated efficacy with both oral (Pankragen-Forte capsules) and intramuscular routes; penetrates cell membranes and nuclear membranes to reach DNA promoter regions; oral bioavailability sufficient for clinical effects at 500 mcg doses
CAS Number
Not definitively assigned
Protocols
Dosing
tiers
SLU-PP-332
Pancragen
Applications
Best
suited for
SLU-PP-332
Metabolic Syndrome Warriors
If you're battling the frustrating combination of belly fat, blood sugar issues, and sluggish metabolism, SLU-PP-332 targets the exact pathways that go haywire in metabolic syndrome. It's like giving your metabolism a personal trainer that works 24/7.
Exercise-Limited Individuals
Injuries, disabilities, or conditions that prevent normal exercise don't have to mean giving up on metabolic health. SLU-PP-332 activates exercise pathways even when you can't hit the gym, potentially maintaining metabolic function during recovery periods.
Endurance Athletes Seeking an Edge
For those already training hard, SLU-PP-332 may amplify your body's natural adaptation to exercise. Research shows it synergizes with actual training, potentially helping you get more benefit from every workout.
Aging Adults Fighting Metabolic Decline
As we age, our mitochondria become less efficient and our metabolism slows. SLU-PP-332 targets the ERR receptors that control mitochondrial function, potentially helping maintain youthful metabolic capacity even as birthdays add up.
Pancragen
Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
Pancragen is particularly well-suited for individuals focused on supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
Pancragen is particularly well-suited for individuals focused on geroprotective pancreatic support to maintain beta-cell differentiation and insulin production. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting metabolic aging
Pancragen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting metabolic aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Pancragen is particularly well-suited for individuals focused on adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
SLU-PP-332
Common
- Mild GI discomfort
- Increased energy
- Mild warmth or temperature increase
Uncommon
- Changes in appetite
- Mild headache
Serious
- Allergic reaction
Pancragen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Mild hypoglycemia
Serious
- No documented serious adverse effects
Research Status
Safety
& evidence
SLU-PP-332
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
SLU-PP-332 has demonstrated a favorable safety profile in extensive preclinical studies. Mouse studies showed no severe adverse events even at relatively high doses, with researchers noting improvements in metabolic markers without negative effects on appetite, behavior, or organ function. The compound appears well-tolerated in animal models, though human clinical trials are still needed to fully establish its safety profile in people.
Contraindications
- xPregnancy or planning to become pregnant
- xCurrently breastfeeding
- xKnown allergy to the compound or similar chemicals
- xChildren and adolescents
- xSevere liver or kidney disease
Pancragen
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, tryptophan)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive hypoglycemia or insulin-secreting tumors (insulinoma) — Pancragen's beta-cell stimulating effects may exacerbate hypoglycemia
- xConcurrent use of sulfonylureas without medical supervision — potential for additive hypoglycemic effects
Decision Guide
Which is
right for you?
Choose SLU-PP-332 if...
- Enhanced metabolic health
- Fat loss without extreme dieting
- Improved exercise endurance
- Supporting mitochondrial function
Choose Pancragen if...
- Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
- Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
- Comprehensive Khavinson bioregulator protocols targeting metabolic aging
- Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance